Comprehensive coronary artery disease care in a safety-net hospital: Results of Get With The Guidelines quality improvement initiative

被引:12
作者
Krantz, Mori J.
Baker, William A.
Estacio, Raymond O.
Haynes, Deborah K.
Mehler, Philip S.
Fonarow, Gregg C.
Long, Carlin S.
机构
[1] Denver Hlth, Cardiac Risk Reduct Program, Denver, CO 80204 USA
[2] Colorado Prevent Ctr, Prevent Dept, Denver, CO USA
[3] Univ Colorado, Denver, CO 80202 USA
[4] Hlth Sci Ctr, Denver, CO USA
[5] Denver Hlth, Coronary Care Unit, Denver, CO USA
[6] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA USA
来源
JOURNAL OF MANAGED CARE PHARMACY | 2007年 / 13卷 / 04期
关键词
coronary artery disease; Get With The Guidelines; safety-net hospital;
D O I
10.18553/jmcp.2007.13.4.319
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
BACKGROUND: Adherence to published coronary artery disease (CAD) guidelines is suboptimal, particularly among minorities and the poor While hospital-based quality-improvement programs may increase the use of evidence-based therapies, little data exist regarding the impact of such programs in sociodemographically disadvantaged (vulnerable) populations. Vulnerable patients in the United States are cared for primarily within the safety-net health system, which comprises urban public hospitals and outpatient community health centers. Denver Health is an example of an integrated system that encompasses both types of facilities. OBJECTIVE: To assess evidence-based medication use in CAD patients after initiation of an inpatient quality-improvement program at Denver Health. METHODS: We reviewed the medical records of 499 patients with angiographically proven CAD who were hospitalized between July 1998 and December 2002. Patients were prospectively identified through a multidisciplinary intervention led by a nurse manager, and their records were input retrospectively into the American Heart Association's Get With The Guidelines patient management tool. The association's program, which recommends initiating 4 cardioprotective drug classes while patients are hospitalized, was started 2 years into the observation period (August 2000). Treatment rates were compared over the ensuing years. We evaluated temporal trends in discharge use of 4 drugs: (1) beta-blockers, (2) angiotensin-converting enzyme inhibitors (ACEIs), (3) hydroxymethylglutaryl coenzyme A reductase inhibitors (statins), and (4) aspirin. We calculated the proportion of eligible patients (no documented contraindication) who were prescribed each drug category as well as the proportion who received all 4 drug categories, our principal composite outcome. If any one drug was absent, the composite criterion was considered unmet. RESULTS: We observed progressive improvement in discharge use of the 4-drug composite: 18% in 1998-1999 (95% confidence interval [CI], 12%-25%), 50% in 2000 (95% Cl, 37%-630,16), 62% (95% Cl, 54%-70%) in 2001, and 72% (65%-79%) in 2002 (P < 0.001 for between-year differences). Among eligible patients discharged in 2002, 90% received beta-blockers, 91% received ACEIs, 86% received statins, and 93% received aspirin. CONCLUSIONS: Implementation of a multidisciplinary program led by a nurse manager was associated with increased CAD guideline compliance among sociodemographically disadvantaged patients. This compliance exceeded national averages. Achievement of the composite measure of use of all 4 recommended drug categories at discharge improved from 18% in 1998-1999 to 72% in 2002.
引用
收藏
页码:319 / 325
页数:7
相关论文
共 31 条
[21]   Usefulness of in-hospital prescription of statin agents after angiographic diagnosis of coronary artery disease in improving continued compliance and reduced mortality [J].
Muhlestein, JB ;
Horne, BD ;
Bair, TL ;
Li, QY ;
Madsen, TE ;
Pearson, RR ;
Anderson, JL .
AMERICAN JOURNAL OF CARDIOLOGY, 2001, 87 (03) :257-261
[22]   Impact of combination evidence-based medical therapy on mortality in patients with acute coronary syndromes [J].
Mukherjee, D ;
Fang, JM ;
Chetcuti, S ;
Moscucci, M ;
Kline-Rogers, E ;
Eagle, KA .
CIRCULATION, 2004, 109 (06) :745-749
[23]   Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease [J].
Newby, LK ;
LaPointe, NMA ;
Chen, AY ;
Kramer, JM ;
Hammill, BG ;
DeLong, ER ;
Muhlbaier, LH ;
Califf, RM .
CIRCULATION, 2006, 113 (02) :203-212
[24]  
Pearson Thomas, 2003, Prev Cardiol, V6, P204, DOI 10.1111/j.1520-037X.2003.02633.x
[25]   Clinical inertia [J].
Phillips, LS ;
Branch, WT ;
Cook, CB ;
Doyle, JP ;
El-Kebbi, IM ;
Gallina, DL ;
Miller, CD ;
Ziemer, DC ;
Barnes, CS .
ANNALS OF INTERNAL MEDICINE, 2001, 135 (09) :825-834
[26]   A "poly-portfolio" for secondary prevention: A strategy to reduce subsequent events by up to 97% over five years [J].
Robinson, JG ;
Maheshwari, N .
AMERICAN JOURNAL OF CARDIOLOGY, 2005, 95 (03) :373-378
[27]   Comparison of outcomes in acute coronary syndrome in patients receiving statins within 24 hours of onset versus at later times [J].
Saab, FA ;
Eagle, KA ;
Kline-Rogers, E ;
Fang, JM ;
Otten, R ;
Mukherjee, D .
AMERICAN JOURNAL OF CARDIOLOGY, 2004, 94 (09) :1166-1168
[28]   CORRELATES OF NONADHERENCE TO HYPERTENSION TREATMENT IN AN INNER-CITY MINORITY POPULATION [J].
SHEA, S ;
MISRA, D ;
EHRLICH, MH ;
FIELD, L ;
FRANCIS, CK .
AMERICAN JOURNAL OF PUBLIC HEALTH, 1992, 82 (12) :1607-1612
[29]   Acute Ischemic Heart Disease - Early initiation of lipid-lowering therapy for acute coronary syndromes improves compliance with guideline recommendations: Observations from the Orbofiban in Patients with Unstable Coronary Syndromes (OPUS-TIMI 16) trial [J].
Smith, CS ;
Cannon, CP ;
McCabe, CH ;
Murphy, SA ;
Bentley, J ;
Braunwald, E .
AMERICAN HEART JOURNAL, 2005, 149 (03) :444-450
[30]   The underutilization of cardiac medications of proven benefit, 1990 to 2002 [J].
Stafford, RS ;
Radley, DC .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 41 (01) :56-61